News & Events about Natera Inc.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart...
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers PR Newswire AUSTIN...
Natera to Present New Signatera and Empower Data at the 2022 Annual San Antonio Breast Cancer Symposium Natera to Present New Signatera and Empower Data at the 2022 Annual San Antonio Breast Cancer Symposium PR Newswire AUSTIN, Texas, Dec. 7, 2022 AUSTIN, Texas, Dec. 7, 2022 /PRNewswire/ -- Natera...
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference PR Newswire AUSTIN, Texas, Nov. 23, 2022 AUSTIN, Texas, Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free...